KROS - NASDAQ

Keros Therapeutics, Inc.

KROS·NASDAQ

$10.77

+2.1%

HealthcareBiotechnology

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$344.62M

EPS2.3400

P/E Ratio4.60

Earnings Date08/05/2026

338.02M

Assets

-45%

3Y+10.0%

5Y+25.0%

10Y+1133.0%

34.89M

Total Liabilities

-21%

3Y+19.0%

5Y+352.0%

10Y+138.0%

303.13M

Total Equity

-47%

3Y+9.0%

5Y+16.0%

10Y+2276.0%

Keros Therapeutics, Inc. Funding & Solvency Profile

KROS · NASDAQ

Current Assets

Cash & Cash Equivalents287.42M

Net Receivables6.37M

Inventory0.00

Other Current Assets21.65M

Total Current Assets315 M

Non-Current Assets

Property, Plant & Equipment21.14M

Goodwill & Intangible Assets0.00

Long-Term Investments1.45M

Other Non-Current Assets0.00

Total Non-Current Assets23 M

Total Assets

338.02M

Financial Health Analysis

Current Ratio

15.45x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.12x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

295 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

93% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Keros Therapeutics, Inc. Balance Sheet

KROS • NASDAQ

Keros Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	287.4M	559.9M	331.1M	279M	230M	265.9M	7M	23.3M
Cash & Short-Term Investments	287.4M	559.9M	331.1M	279M	230M	265.9M	7M	23.3M
Net Receivables	6.4M	4.5M	1.1M	841K	18.2M	216K	922K	0.0
Accounts Receivables	3.6M	2.7M	143K	841K	18M	0.0	0.0	0.0
Other Receivables	2.8M	1.7M	948K	0.0	197K	216K	922K	0.0
Prepaids	0.0	23M	14.1M	5.6M	3M	1.5M	166K	2.2M
Other Current Assets	21.6M	1.5M	1M	276K	210K	160K	819K	84K
Total Current Assets	315.4M	588.9M	347.3M	285.8M	251.4M	267.7M	8.9M	25.5M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	21.1M	23.5M	19.5M	17.6M	2.4M	1.6M	1.9M	1.4M
Long-Term Investments	1.4M	1.4M	1.2M	0.0	0.0	0.0	0.0	501K
Other Non-Current Assets	0.0	2.1M	2.1M	3.4M	1.4M	115K	115K	0.0
Total Non-Current Assets	22.6M	27M	22.7M	21M	3.8M	1.7M	2M	1.9M
Total Assets	338M	615.9M	370M	306.8M	255.3M	269.4M	11M	27.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2M	4.6M	5.5M	3.3M	3.8M	2.3M	2.1M	785K
Accounts Payable	2M	4.6M	5.5M	3.3M	3.6M	2.1M	2.1M	501K
Other Payables	0.0	0.0	0.0	0.0	110K	185K	43K	284K
Accrued Expenses	0.0	10.3M	7.5M	7.2M	4.7M	2.7M	961K	41K
Short Term Debt	2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	2M	1M	455K	862K	423K	376K	166K
Tax Payables	0.0	0.0	0.0	50K	110K	185K	43K	284K
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10M
Other Current Liabilities	16M	10.5M	10.4M	5.6M	2.6M	1.7M	1M	477K
Total Current Liabilities	20.4M	27.5M	24.4M	16.5M	11.8M	7.2M	4.5M	11.5M
NON-CURRENT LIABILITIES
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	62K	5.1M	2.6M
Total Non-Current Liabilities	14.5M	16.9M	13.4M	12.8M	231K	538K	6M	3.2M
Capital Lease Obligations	14.5M	18.9M	14.4M	13.3M	1.1M	899K	1.3M	788K
Total Liabilities	34.9M	44.3M	37.8M	29.4M	12.1M	7.7M	10.5M	14.7M
SHAREHOLDERS' EQUITY
Treasury Stock	-384.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	19.9M	19.9M
Common Stock	4K	4K	3K	2K	2K	2K	1K	1K
Additional Paid-In Capital	1.2B	1.1B	713.6M	505.9M	366.9M	326.7M	203K	130K
Retained Earnings	-481.8M	-568.8M	-381.4M	-228.4M	-123.8M	-65M	-19.7M	-7.3M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-246K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	246K
Total Stockholders' Equity	303.1M	571.6M	332.2M	277.4M	243.2M	261.7M	495K	12.8M
Total Equity	303.1M	571.6M	332.2M	277.4M	243.2M	261.7M	495K	12.8M
SUMMARY
Total Liabilities & Equity	338M	615.9M	370M	306.8M	255.3M	269.4M	11M	27.4M
Total Investments	1.4M	1.4M	1.2M	0.0	0.0	0.0	0.0	501K
Total Debt	16.9M	18.9M	14.4M	13.3M	1.1M	899K	1.3M	788K
Net Debt	-270.5M	-541.1M	-316.7M	-265.8M	-228.9M	-265M	-5.7M	-22.5M
Shares Outstanding	40,538,613	40,538,613	40,538,613	40,538,613	40,538,613	40,538,613	40,538,613	40,538,613

SEC Filings

KROS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 03, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	June 01, 2026	June 01, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 22, 2026	June 03, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 09, 2026	March 09, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 04, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 04, 2026	March 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 20, 2026	2026	View Filing

Showing 1 to 10 of 181 filings

Related Guides

Blog Categories

Continue your KROS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.